

Resource Summary Report

Generated by [NIF](#) on Sep 1, 2026

AKT Serine/Threonine Kinase 1 Peptide 2 antibody - Clinical Proteomics Technologies for Cancer; National Cancer Institute

RRID:AB_2722014

Type: Antibody

Proper Citation

DSHB Cat# CPTC-AKT1-3, RRID:AB_2722014

Antibody Information

URL: http://antibodyregistry.org/AB_2722014

Proper Citation: DSHB Cat# CPTC-AKT1-3, RRID:AB_2722014

Target Antigen: AKT Serine/Threonine Kinase 1 Peptide 2

Host Organism: mouse

Clonality: monoclonal

Comments: Application(s): Date Deposited: 05/10/2017

Antibody Name: AKT Serine/Threonine Kinase 1 Peptide 2 antibody - Clinical Proteomics Technologies for Cancer; National Cancer Institute

Description: This monoclonal targets AKT Serine/Threonine Kinase 1 Peptide 2

Target Organism: human

Antibody ID: AB_2722014

Vendor: DSHB

Catalog Number: CPTC-AKT1-3

Record Creation Time: 20250819T230022+0000

Record Last Update: 20250820T035946+0000

Ratings and Alerts

No rating or validation information has been found for AKT Serine/Threonine Kinase 1 Peptide 2 antibody - Clinical Proteomics Technologies for Cancer; National Cancer Institute.

No alerts have been found for AKT Serine/Threonine Kinase 1 Peptide 2 antibody - Clinical Proteomics Technologies for Cancer; National Cancer Institute.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Whiteaker JR, et al. (2021) Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Cell reports methods, 1(3).

Petralia F, et al. (2020) Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell, 183(7), 1962.